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Peter D Friedmann1* and Robert P Schwartz2Abstract
Although many in the addiction treatment field use the term “medication-assisted treatment” to describe a
combination of pharmacotherapy and counseling to address substance dependence, research has demonstrated
that opioid agonist treatment alone is effective in patients with opioid dependence, regardless of whether they
receive counseling. The time has come to call pharmacotherapy for such patients just “treatment”. An explicit
acknowledgment that medication is an essential first-line component in the successful management of opioid
dependence.
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Substance abuse treatment.The recently published National Institute on Drug Abuse
Clinical Trials Network’s Prescription Opiate Treatment
Study (POATS) [1] found that only 6.6% of prescription-
opioid dependent participants had minimal or no opioid
use following brief treatment with buprenorphine/naloxone
(BUP/NX). Patients enrolled in that trial who returned to
opioid use on discontinuation of BUP/NX resumed BUP/
NX for an extended period. Although 49.2 % of those
patients who resumed BUP/NX had a successful outcome
at the final week of the extended BUP/NX treatment, the
success rate dropped to 8.6% at eight weeks after a two-
week dose taper. In neither case did individual opioid de-
pendence counseling (45–60 minute weekly sessions with a
trained mental health or substance abuse professional) pro-
vide additional benefit over standard medical management
(15–20 minute visits with a physician certified to prescribe
BUP/NX).
Increasingly, practitioners, administrators, and policy-
makers in the addiction treatment field have taken to
using the terms “medication-assisted treatment” or
“medication-assisted recovery” to describe the combin-
ation of pharmacotherapy with counseling and/or recov-
ery work. Recovery-movement traditionalists have
maintained that addiction remission is not genuine if
produced through use of medication alone, because the
person has not undergone the interpersonal and spiritual* Correspondence: pfriedmann@lifespan.org
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distribution, and reproduction in any mediumchanges deemed necessary for lasting recovery. The
terms medication-assisted treatment and medication-
assisted recovery manifest this perspective. Such terms
bespeak an implicit judgment that medication is only an
adjunct to the “truly effective components” of counseling
and recovery work.
Terminology is meaningful in a field because it both
reflects and influences the beliefs of practitioners. The
view that pharmacotherapy-induced remission is less
valuable than “real” recovery stigmatizes patients, provi-
ders, and the therapy itself. The view of medication as a
temporary adjunct opens the door for rejection of
patients on medication at some self-help meetings, time
limits on insurance coverage for addiction medication,
and preference for medication tapering on the part of
patients, practitioners and criminal justice professionals,
despite evidence that this approach leads to inferior and
sometimes adverse outcomes, including death [2]. Such
views are contrary to the modern perspective on opioid
dependence, that many patients should be treated as
having a chronic neurobehavioral brain disorder.
Although one earlier clinical trial conducted among
veterans suggested that adding counseling to methadone
increased opioid agonist treatment (OAT) efficacy [3],
much research prior to the POATS has demonstrated
that pharmacotherapy alone is effective treatment for
opioid dependence with minimal to no drug-abuse
counseling. A recent Cochrane systematic review of the
literature found that OAT without counseling is more
effective than being waitlisted for treatment or receivingMed Central Ltd This is an Open Access article distributed under the terms of
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addition, randomized clinical trials have provided strong
evidence for the effectiveness of directly administered
methadone without drug abuse counseling for one
month [5], four months [6], and six months [7].
Throughout the world, OAT is commonly delivered
with minimal or no counseling beyond standard medica-
tion management, with rates of treatment retention and
improvement in illicit drug use comparable to OAT with
counseling [8-12]. In the United States, a study on
office-based buprenorphine treatment also found that
intensive counseling with OAT was no more effective
than opioid agonist pharmacotherapy with standard
medication management [13].
The POATS findings and other rigorous studies dem-
onstrate that OAT is effective in suppressing opioid use
as long as it is maintained, and that a tapering detoxifi-
cation strategy, regardless of duration, fails the great ma-
jority of opioid-dependent patients [14-16]. As with the
treatment of hypertension or diabetes, as long as the pa-
tient takes the medication, the disorder’s manifestations
are mitigated; when the medication is stopped, those
manifestations recur [17]. For many patients seeking
treatment for opioid dependence, drug abuse counseling
does not appear to add any measurable improvement in
outcome beyond prescribed buprenorphine with stand-
ard medication management delivered in an office-based
setting [1], or direct administration of methadone with-
out counseling in an opiate treatment program [7,18].
It should not be construed that drug abuse counseling
is without value. Such counseling should be offered to
patients, but patient resistance to counseling should not
be a barrier to receiving highly effective medication,
such as methadone or buprenorphine, any more than in-
sulin should be withheld from diabetic patients who re-
fuse dietary counseling. Perhaps for this reason, the
World Health Organization has called effective treat-
ment for opioid dependence psychosocially-assisted
pharmacotherapy [19].
Counseling-assisted pharmacotherapy has also been
suggested as a term that reflects the true relative effect-
iveness of these treatment modalities [20]. However,
other medical disciplines do not use the modifer
“-assisted” to describe multimodal treatment. Type-2
diabetics take medication and get counseling about
weight loss, diet and exercise; all are important, and
none is viewed as “assisting.” The time has come to call
medication therapy for addiction just “treatment”—an
explicit acknowledgment that pharmacotherapy is an es-
sential component and common first-line treatment for
opioid dependence.
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